In June 2024, RemeGen, a Chinese biopharmaceutical company, announced a landmark licensing agreement with global pharmaceutical giant AbbVie. Under the terms of the deal, RemeGen granted AbbVie exclusive rights to develop and commercialize its proprietary antibody-drug conjugate (ADC), RC88—which targets mesothelin—outside Greater China. As part of the transaction, RemeGen will receive an upfront payment and near-term milestones totaling $600 million, with the potential to earn up to an additional $1.75 billion in future milestone payments, plus tiered royalties on net sales.This collaboration underscores international recognition of RemeGen’s innovative R&D capabilities and reflects the growing influence of Chinese originator biotechs in the global pharmaceutical landscape. RC88, a mesothelin-targeting ADC, is currently being evaluated for the treatment of various solid tumors, including ovarian and pancreatic cancers—areas of high unmet medical need. Partnering with AbbVie is expected to accelerate RC88’s global clinical development and bring the therapy to patients worldwide more rapidly.For RemeGen, the deal not only provides significant non-dilutive funding to advance its pipeline but also represents a strategic leap forward in its global expansion. Moreover, it highlights the immense value and momentum of the ADC field as a key frontier in modern drug discovery.
2024年6月，中国生物制药企业荣昌生物宣布与全球知名制药公司艾伯维（AbbVie）达成一项重磅授权许可协议。根据协议，荣昌生物将其自主研发的抗体偶联药物（ADC）RC88（靶向间皮素）在大中华区以外的全球开发和商业化权利独家授权给艾伯维。作为交易的一部分，荣昌生物将获得6亿美元的首付款及近期里程碑付款，并有资格在未来获得最高达17.5亿美元的额外里程碑付款，以及基于净销售额的分级特许权使用费。此次合作标志着荣昌生物的创新研发能力获得国际巨头认可，也体现了中国原研药企在全球生物医药产业链中的地位不断提升。RC88作为一种靶向间皮素的ADC药物，目前正用于治疗多种实体瘤，包括卵巢癌、胰腺癌等高未满足临床需求的癌症类型。通过与艾伯维的合作，该药物有望加速其全球临床开发进程并更快惠及全球患者。对荣昌生物而言，这笔交易不仅带来可观的现金流支持后续管线研发，也为其国际化战略迈出关键一步。同时，该合作也彰显了ADC领域作为当前全球新药研发热点的重要价值。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/13174.html